Clinical and histological predictors of contralateral breast cancer

Kollias, James; Ellis, Ian O.; Elston, C. W.; Blamey, R. W.

doi:10.1053/ejso.1999.0711

Cited by 94 publications

(71 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study population, younger age at incidence of the initial breast cancer was a risk factor for CBC as also found in various other studies (Bernstein et al 2003;Chen et al 1999;Hartman et al 2007;Kollias et al 1999;Kurian et al 2009;Lizarraga et al 2013;Narod 2014;Nichols et al 2011;Rubino et al 2010;Sandberg et al 2012b;Schaapveld et [8] al. 2008; Verkooijen et al 2007;Vichapat et al 2011a).…”

Section: Discussionsupporting

confidence: 86%

“…Lobular cancer is frequently seen as a risk factor for CBC (Arpino et al 2004;Bernstein et al 2003;Chen et al 1999;Kollias et al 1999;Lizarraga et al 2013;Narod 2014;Schaapveld et al 2008;Soran et al 2014), but not all studies show this result (Lizarraga et al 2013;Narod 2014;Rubino et al 2010;Verkooijen et al 2007;Vichapat et al 2011b). Invasive lobular carcinoma represents about 10-15% of breast cancers.…”

Section: Discussionmentioning

confidence: 99%

“…As in some other studies older patients -older than 84 years of age in our case -were not included because of the insufficient follow-up of older patients (Font-Gonzalez et al 2013;Kollias et al 1999;Nichols et al 2011). Patients younger than 20 were also excluded because of the small number of cases (n=1175).…”

Section: Methodsmentioning

confidence: 99%

“…The risk of a new occurrence of breast cancer is significantly increased compared to the general risk of developing breast cancer (Bernstein et al 2003;Kollias et al 1999;Lizarraga et al 2013;Rubino et al 2010;Sandberg et al 2012a). The annual risk of developing a second invasive tumour of the opposite breast has been reported to be between 0.3-0.8% (Kollias et al 1999;Lizarraga et al 2013;Narod 2014;Nichols et al 2011). This means a woman with breast cancer has approximately a doubled risk of developing a second primary tumour of the breast compared to the risk of breast cancer in the general female population (Sandberg et al 2012a).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

Prater¹,

Valeri

Korol³

et al. 2015

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

PURPOSE To examine the incidence and characteristics of metachronous contralateral breast cancer (CBC) among women in the Canton of Zurich, Switzerland. METHODS For 1980-2006 with unilateral invasive breast cancer (UBC) were analysed for metachronous CBC. Poisson's regression was used to estimate incidence rates of metachronous CBC according to age, year of diagnosis, follow-up period since first breast cancer and morphology. RESULTS Of 16,323 patients with UBC, 700 (4.3 %) developed a second malignant tumour of the opposite breast. Median age at first breast cancer was lower in the CBC group than in the full cohort. Median interval time between first and second breast cancer was 5.5 (interquartile range 2.6-10.1) years. Incidence rate at age 20-29 was 1006 (95 % confidence interval, CI, 452-2238) cases per 100,000 person-years and decreased to 299 (199-450) at 80-84. Age-adjusted incidence rates according to period of diagnosis decreased from 618 (530-721) for 1980-1984 to 329 (217-500) cases per 100,000 person-years for [2005][2006]. Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95 % CI 0.99-1.67) adjusted by age group and period of diagnosis compared to ductal carcinoma. CONCLUSIONS In our study, incidence rates for CBC are comparable with findings from the literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant therapies, is seen in our data. In our cohort, younger age and lobular carcinoma were associated with an increased risk of CBC. Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95% CI 0.99 -1.67) adjusted by age group and period of diagnosis compared to ductal carcinoma.Conclusions: In our study, incidence rates for CBC are comparable with findings from the literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant therapies, is seen in our data. In our cohort, younger age and lobular carcinoma was associated with increased risk for CBC.Keywords Metachronous contralateral breast cancer, lobular carcinoma, incidence rates, year of diagnosis, follow-up period [3]

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

Prater¹,

Valeri

Korol³

et al. 2015

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Annual incidence of CBC increases during the follow-up of breast cancer survivors. Common CBC risk factors were confirmed in our population, apart from tumor lobular histology and hormone receptors [18,[27][28][29][30][31]. When considering BMI as an independent risk factor for CBC, CBC events are expected to increase along with improved breast cancer survival [29] and the given worldwide epidemic of overweight and obesity [19].…”

Section: Discussionmentioning

confidence: 77%

Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association

Majed

Dozol

Ribassin-Majed

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Neoplasms of the Breast

Rugo

Majure

Dragun

et al. 2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Breast cancer in women remains a major medical problem with significant public health and societal ramifications, including issues related to screening, risk factors, prevention, diagnosis, treatment, and survival following diagnosis. Major advances have markedly improved the understanding of clinical phenotypes, as well as the biologic pathways that drive tumor growth and resistance. This research has led to dramatic changes in treatment that have contributed to a significant reduction in breast cancer mortality over the last two decades, and is the basis of ongoing clinical research. Molecular profiling has provided insights into the heterogeneity of breast cancer subtypes; combining biology and tumor burden has allowed stratification of both risk and treatment to begin the process of individualizing screening, prevention, and treatment. As new information accumulates, new paradigms of management become the standard of care reflected in international guidelines. Our challenge is to apply new formation and treatment appropriately and effectively, and to understand both response and resistance. Information obtained from molecular, biologic, and pathologic investigations and clinical trials provides the major focus of this chapter.

show abstract

Clinical and histological predictors of contralateral breast cancer

Cited by 94 publications

References 31 publications

Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association

Neoplasms of the Breast

Contact Info

Product

Resources

About